副肿瘤性视神经病变的独特临床特征
该研究回顾性纳入2015年1月至2017年6月中国人民解放军总医院神经眼科收治的7例抗体介导的副肿瘤性视神经病变(PON)患者(13只眼),分析其临床特征与预后。结果显示双侧受累常见(5/7,71.4%),严重视力丧失(≤0.1)见于76.9%(10/13)的患眼,所有患者均有副肿瘤相关抗体证据,5例有原发恶性肿瘤史。结论认为PON相对罕见,以双侧受累为主且视力预后较差,副肿瘤抗体检测有助于诊断并帮助早期发现原发肿瘤。
要点
- PON患者双侧同时或早期序贯受累常见(5/7,71.4%)。
- 严重视力丧失(≤0.1)见于76.9%(10/13)患眼,预后较差。
- 所有患者均有副肿瘤相关抗体证据,抗体检测有助于诊断和早期发现肿瘤。
核心结论
- PON相对罕见,以双侧受累为主,视力预后较差。
- 副肿瘤抗体检测有助于PON诊断,并帮助医生更早发现原发肿瘤以指导进一步治疗。
研究设计与样本
- 回顾性收集2015年1月至2017年6月中国人民解放军总医院神经眼科收治的诊断为PON的住院患者临床资料。
- 共纳入7例患者(4女3男,13只患眼),平均年龄56.28±11.32岁(范围36-70岁)。
主要发现
- 双侧同时或早期序贯受累见于5/7(71.4%)患者。
- 严重视力丧失(≤0.1)见于76.9%(10/13)患眼。
- 13只眼处于急性期,其中6只眼表现为视盘水肿。
- 所有患者均有明确的副肿瘤相关抗体证据:3例血清抗amphiphysin抗体阳性,1例抗PNMA2(Ma2/Ta)阳性,1例抗Yo阳性,1例抗Ma2阳性,1例抗CV2阳性。
- 所有血清样本髓鞘少突胶质细胞糖蛋白抗体均为阴性,2例患者合并水通道蛋白-4抗体血清阳性。
关键数值与推荐
- 严重视力丧失定义为视力≤0.1,见于76.9%(10/13)患眼。
- 5例患者有原发恶性肿瘤史,包括甲状腺癌、B型胸腺瘤、睾丸精原细胞瘤、宫颈癌和肺癌。
- 2例患者副肿瘤综合征抗体阳性(抗Yo和抗amphiphysin),但PET扫描未发现实体肿瘤。
- 随访时9/13(69.2%)患眼视力低于0.1,所有患者均存活且无转移病灶。
临床怎么用
- 对疑似PON患者应进行副肿瘤相关抗体检测以辅助诊断。
- 抗体检测结果可帮助医生更早发现原发肿瘤,从而指导进一步治疗。
局限性
- 本研究为回顾性研究,样本量小(共7例患者)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Paraneoplastic optic neuropathy (PON) is relatively uncommon, and the visual outcomes and prognosis of this disease have not been well documented. The aim of this study was to investigate the clinical features and prognosis of antibody-mediated PON. METHODS: Clinical data were retrospectively collected from hospitalised patients diagnosed with PON at the Neuro-Ophthalmology Department at the Chinese People's Liberation Army General Hospital from January 2015 to June 2017. RESULTS: A total of seven patients (four females and three males, 13 involved eyes) were included with a mean age of 56.28±11.32 years (36-70 years). Simultaneous or early sequential bilateral eye involvement (5/7, 71.4%) was common in the patients with PON. Severe vision loss (≤0.1) was seen in 76.9% (10/13) of the eyes. There were 13 eyes in the acute phase of the disease, and six eyes presented with optic disc oedema. All patients had definite evidence of paraneoplastic-associated antibodies (three with serum positive for antiamphilphysin, one for anti-PNMA2 (Ma2/Ta), one for anti-Yo, one for anti-Ma2 and one for anti-CV2). All of the serum samples were negative for myelin oligodendrocyte glycoprotein antibody and two patients companied with seropositive for the aquaporin-4 antibody. Five patients had history of primary malignancy, including thyroid cancer, type B thymoma, testicular seminoma, cervical cancer and lung carcinoma. Two patients had positive paraneoplastic syndrome antibodies (anti-Yo and antiamphiphysin), but the solid tumour had not been found through a PET scan. Visual acuity in 9/13 (69.2%) eyes was below 0.1, and all of the patients survived to the follow-up with no metastatic lesions. CONCLUSIONS: PON is relative rare, with a predominance of bilateral involvement and more with a poor visual prognosis. Paraneoplastic antibody testing can contribute to the diagnosis of PON, distinct from other types of optic neuropathies, which can help doctors to find the primary cancer earlier to guide further treatment.
引用
- Xu Q, Du W, Zhou H, et al. Distinct clinical characteristics of paraneoplastic optic neuropathy. Br J Ophthalmol. 2018. PMID: 30021813. doi:10.1136/bjophthalmol-2018-312046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。